New York-based Intra-Cellular Therapies announced the pricing of its underwritten IPO of 4,750,000 shares at $24 per share, in hopes of raising about $106.5 million. On September 9, the company announced positive topline results from its Phase III Study 402 clinical trial of lumateperone as adjunctive therapy to lithium or valproate to treat major depressive episodes associated with Bipolar I or Bipolar II disorder. The study found that once-daily lumateperone 42 mg hit the primary endpoint for improvement in depression. It was measured by change from baseline compared to placebo on the MADRS total score. It also met the key secondary endpoint of CGI-BP-S Depression Score.
